|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our study suggests that rs4880 and rs4244285 polymorphisms play an important role in development of breast cancer in an Iraqi population, and no significant association was found between rs1801274 and the risk of breast cancer.
|
29482947 |
2018 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect of MnSOD (p.Val16Ala, rs4880) and CAT (-262C>T, rs1001179) SNPs on the association between the MD and BC risk in the case-control study of BC MASTOS in Cyprus.
|
26130326 |
2016 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall survival (OS), breast cancer-specific survival (BCSS), and relapse-free survival (RFS), assessed by using Kaplan-Meier survival analysis and multivariate Cox regression analysis, were evaluated according to the adjuvant treatments and the rs4880 and rs13181 genotypes.
|
24716840 |
2014 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
A polymorphism in its encoding gene (SOD2: Val16Ala rs4880) may confer poorer breast cancer survival, but data are inconsistent.
|
24498107 |
2014 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that MnSOD 47T>C polymorphism in interaction with long-term HRT use may modify the risk of breast cancer.
|
21567099 |
2011 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The variant allele frequencies of SOD2 Val1</span>6Ala (TC or CC type) were 26% for the control subjects and 23% for the breast cancer patients, and the variant genotype was not a risk factor for breast cancer.
|
21056286 |
2010 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, no significant associations were found between MnSOD Val1</span>6Ala polymorphism and breast cancer risk when all studies pooled into the meta-analysis (Val/Ala vs. Val/Val: OR = 1.022, 95% CI = 0.981-1.064; Ala/Ala vs. Val/Val: OR = 1.006, 95% CI = 0.934-1.083; dominant model: OR = 1.013, 95% CI = 0.962-1.066; and recessive model: OR = 0.985, 95% CI = 0.931-1.042).
|
20143154 |
2010 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer.
|
20082851 |
2010 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Manganese superoxide dismutase: effect of the ala16val polymorphism on protein, activity, and mRNA levels in human breast cancer cell lines and stably transfected mouse embryonic fibroblasts.
|
19756960 |
2010 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Conclusively, this meta-analysis strongly suggests that SOD2 Val16Ala polymorphism is not associated with breast cancer susceptibility.
|
20052533 |
2010 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Val16Ala was significantly associated with breast cancer outcome in both patient populations.
|
19509150 |
2009 |
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data seem to suggest that individuals who never breast fed with MnSOD Val16Ala variant allele are at a lower risk for breast cancer, but larger studies are required to confirm these results.
|
16969494 |
2006 |